Zachary Bessette

GU Oncology Now

The National Comprehensive Cancer Network (NCCN) now includes <a href="https://guoncologynow.com/post/dr-brian-helfand-on-the-spotlight-study-recurrent-prostate-cancer-detection-with-18f-rhpsma-7-3" target="_blank" rel="noopener">flotufolastat F 18 (POSLUMA)</a> in its clinical practice guidelines for prostate cancer (version 2.2023).The injection is included in the NCCN guideline recommendations for all the same categories as other prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging agents approved by the US Food and Drug Administration (FDA).Blue Earth Diagnostics, the developer of flotufolastat F 18, announced this addition in late July. The injection was <a href="https://guoncologynow.com/post/posluma-becomes-first-and-only-fda-approved-psma-targeted-pet-imaging-agent" target="_blank" rel="noopener">approved by the FDA</a> in late May as the only PET of PSMA-positive lesions in men with prostate cancer and suspected metastasis who are candidates for initial definitive therapy or with suspected recurrence based on elevated prostate-specific antigen level.&ldquo;The addition of POSLUMA to the highly respected NCCN guidelines is a major milestone for Blue Earth Diagnostics,&rdquo; said David E. Gauden, DPhil, CEO of Blue Earth Diagnostics, in a <a href="https://www.businesswire.com/news/home/20230725319846/en" target="_blank" rel="noopener">press release</a>. &ldquo;We believe it further validates the clinical utility of POSLUMA in patients with newly diagnosed or recurrent prostate cancer and can help expand patient access.&rdquo;With regard to PET imaging for identifying bone metastases, the guidelines state that flotufolastat F 18 should be used for &ldquo;equivocal results on initial bone scan&rdquo; along with sodium fluoride F 18, choline C 11, and fluciclovine F 18. As an alternative to bone scans, the guidelines indicate full-body imaging with PET/computed tomography or PET/magnetic resonance imaging using flotufolastat F 18, Ga-68 PSMA-11, or piflufolastat F 18 PSMA.Flotufolastat F 18 joins piflufolastat F 18 PSMA and Ga-68 PSMA-11 as the other FDA-approved PSMA radiopharmaceuticals available for use.&ldquo;POSLUMA was developed to assist physicians in the detection and localization of prostate cancer,&rdquo; said Eugene J. Teoh, MBBS, MRCP, FRCR, DPhil, CMO of Blue Earth Diagnostics, in the press release. &ldquo;This update recognizes the important ability of PSMA PET imaging procedures to detect and localize newly diagnosed and biochemically recurrent prostate cancer, which are essential to making appropriate patient management decisions.&rdquo;

Flotufolastat F 18 Added to NCCN Clinical Practice Guidelines for Prostate Cancer

Radioligand therapy prostate-specific membrane antigen

The National Comprehensive Cancer Network now includes flotufolastat F 18 (POSLUMA) in its clinical practice guidelines for prostate cancer.

Flotufolastat F 18 Added to NCCN Guidelines for Prostate Cancer

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtables

The Uromigos

Uromigos Live 2024

AUC3

Localized

mHSPC/mCSPC

CRPC

Diagnostics

Prostate Cancer

Localized Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

nccRCC

Renal Cell Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Video Insights

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe